Celcuity Drug Patent Portfolio

Celcuity owns 1 orange book drug protected by 7 US patents Given below is the list of Celcuity's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12350276 Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea 31 Aug, 2042
Active
US12109308 Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea 02 Jan, 2041
Active
US8039469 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 17 Dec, 2029
Active
US8217036 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 22 May, 2029
Active
US8575159 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 22 May, 2029
Active
US8748421 Triazine Compounds As P13 Kinase And Mtor Inhibitors 22 May, 2029
Active
US9174963 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 22 May, 2029
Active


Celcuity's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Celcuity:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) Celcuity Inc NA RECRUITING
(May 1, 2026)
PHASE3
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Celcuity Inc NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2


Celcuity Drug List

Given below is the complete list of Celcuity's drugs and the patents protecting them.


1. Revtorpyk

Revtorpyk is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12350276 Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea 31 Aug, 2042
(15 years from now)
Active
US12109308 Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea 02 Jan, 2041
(14 years from now)
Active
US8039469 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 17 Dec, 2029
(3 years from now)
Active
US8217036 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 22 May, 2029
(2 years from now)
Active
US8575159 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 22 May, 2029
(2 years from now)
Active
US8748421 Triazine Compounds As P13 Kinase And Mtor Inhibitors 22 May, 2029
(2 years from now)
Active
US9174963 Triazine Compounds As Pi3 Kinase And Mtor Inhibitors 22 May, 2029
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Revtorpyk's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List